LUMA-VISION
18.12.2023 09:01:37 CET | Business Wire | Press release
LUMA Vision, developer of a novel four-dimensional (4D) cardiac imaging and navigation platform, today announced a total of $22 million in new financing for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218234415/en/
LUMA Vision Co-Founders, CEO Fionn Lahart (right) and Chief Technology Officer Christoph Hennersperger (left). (Photo: Business Wire)
The Series A3 financing added three new investors comprising an undisclosed multinational strategic investor, Atlantic Bridge Growth Fund and Bayern Kapital, and was led by existing investors EQT Lifesciences, ABV Uni Fund and imec.xpand. The new funding adds to prestigious grants won earlier by LUMA Vision from the Irish government’s Disruptive Technologies Innovation Fund ($6 million) and the European Union’s EIC Accelerator ($3 million).
LUMA Vision will use the new funds to gain FDA clearance, prepare for U.S. commercialization and develop the next generations of its VERAFEYE platform for additional clinical applications in cardiology and beyond.
LUMA Vision has developed VERAFEYE™, a novel all-in-one 4D imaging and navigation platform with data-driven software applications designed for cardiology. The technology uses a proprietary catheter sensor combined with advanced digital imaging and deep learning to provide unprecedented, high-resolution, 360-degree imagery of the beating heart and surrounding anatomy. VERAFEYE can be used with other catheters or systems during cardiac surgery and, with multiple applications in one platform, can provide all of the imaging guidance needed during cardiac surgery in real time without the need for external systems such as X-ray or CT.
VERAFEYE will provide cardiologists with accurate, precise and comprehensive anatomical data required to guide personalized patient therapy across a variety of diseases, such as atrial fibrillation, left atrial appendage closure and cardiac valve replacement.
Professor Gabor Szlepaki, Head of Cardiac Electrophysiology at the Mater Private Hospital Dublin and Centre Clinical lead of the Atrial Fibrillation Institute, added, “This new technology has the potential to help us deliver more precise therapies for patients suffering from abnormal heart rhythms or structural heart problems. This type of medical innovation is essential for the continuous progression of minimally invasive cardiac therapies that can improve patient care.”
“Physicians require accurate, real-time data at the point of care in order to effectively treat patients,” said LUMA Vision CEO Fionn Lahart. “Our goal with VERAFEYE is to provide the data and imaging physicians need in one system to successfully treat as many of the conditions their patients face as possible. By developing a technology platform that can be tailored for specific therapies in cardiology, we believe that VERAFEYE can be a bedrock of medical imaging for many years to come.”
He continued, “We are absolutely delighted to welcome to the company our new investors and gratified to secure the continued backing of our highly regarded existing investors. As a truly pan-European startup with offices in Dublin and Munich, we have grown our team significantly in the last three years and will continue to add world-class talent to help LUMA Vision achieve its goals.”
ABOUT LUMA Vision
LUMA Vision (formerly known as OneProjects Ltd) is a privately held, venture-backed medical device company based in Dublin, Ireland and Munich, Germany. LUMA Vision was originally a spin out company from Bioinnovate Ireland and Trinity College Dublin. The company designs and develops an innovative 4D imaging and navigation end-to-end platform for cardiac applications to deliver data at the point of therapy. LUMA Vision was founded by CEO Fionn Lahart and Chief Technology Officer Christoph Hennersperger. Learn more about LUMA Vision and VERAFEYE™ at www.lumavision.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231218234415/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom